3SBio : NOTIFICATION OF INTERIM RESULTS ANNOUNCEMENT

(Incorporated in the Cayman Islands with limited liability)

3SBio Inc. (the "Company") published its interim results announcement for the six months ended 30 June 2017 on 28 August 2017 on this website for its stock code 1530. The Company wishes to inform its investors that a corresponding copy of the interim results announcement, which is attached hereto, is also available on this website for its convertible bond code 5241.

By order of the Board

Chairman

Shenyang, the PRC 29 August 2017

As at the date of this announcement, the directors of the Company are Dr. LOU Jing, Mr. TAN Bo, Ms. SU Dongmei and Mr. HUANG Bin as executive directors; Mr. LIU Dong and Mr. WANG Steven Dasong as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Mr. MA Jun as independent non-executive directors.

(Incorporated in the Cayman Islands with limited liability)

• Revenue1increased by approximately RMB401.9 million or approximately 30.8% to approximately RMB1,706.7 million, as compared to the six months ended 30 June 2016.

• Gross profit1increased by approximately RMB323.9 million, or approximately 28.6% to approximately RMB1,457.1 million, as compared to the six months ended 30 June 2016, and gross profit margin was approximately 85.4%.

• EBITDA1, 2increased by approximately RMB162.6 million or approximately 33.2% to approximately RMB652.7 million, as compared to the six months ended 30 June 2016.

• Net profit1, 3increased by approximately RMB99.6 million or approximately 34.3% to approximately RMB389.6 million, as compared to the six months ended 30 June 2016.

Notes:

1. The financial information of Shanghai CP Guojian Pharmaceutical Co., Ltd. (now known as Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ( 三生國健藥業( 上海) 股份有限公司), "Sunshine Guojian") was consolidated into the Group's financial statements since 1 April 2016.

2. The normalized EBITDA increased by approximately RMB112.1 million or approximately 20.2% to approximately RMB667.0 million, as compared to the six months ended 30 June 2016. The normalized EBITDA is defined as the EBITDA for the period excluding, as applicable: (a) the expenses incurred in relation to the issuance of the Bonds (as defined below); (b) the option expenses associated with options granted on 2 February 2017; (c) the expenses incurred in relation to the acquisition of Sunshine Guojian; (d) the warrant expenses associated with the issue of the warrants granted to the management of Sunshine Guojian (the "Sunshine Guojian Warrants") on 1 January 2015; and (e) the income associated with the fair value gain of the approximately 28.8% equity interests in Sunshine Guojian previously acquired by the Group in 2014 and 2015.

3. The normalized net profit increased by approximately RMB49.0 million, or approximately 13.8%, to approximately RMB403.8 million, as compared to the six months ended 30 June 2016. The normalized net profit is defined as the profit for the period excluding the same items as listed in Note 2 above.

The board (the "Board") of directors (the "Directors") of 3SBio Inc. ("3SBio" or the "Company") is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (collectively, the "Group") for the six months ended 30 June 2017, together with the comparative figures for the corresponding period in 2016 as follows:

RMB'000 RMB'000

Other comprehensive income/(loss) to be reclassified to profit or loss in subsequent periods:

Change in fair value of available-for-sale investments,

Net other comprehensive loss to be reclassified

to profit or loss in subsequent periods (47,956) (8,532)